This medication is a cream applied to the skin to treat chronic hand eczema, a long-term condition that causes itching, dryness, scaling, and redness on the hands and wrists. It works by blocking certain proteins in the body involved in skin inflammation.[2] Anzupgo is currently approved and in use across 13 indications[4].[1]
Anzupgo is one of 191 small molecule programs targeting Palmoplantar Pustulosis. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
1050 competitors in Asthma
Anzupgo
Veramyst
Xolair
Singulair
Dupixent
Celexa
Spiriva
Aciphex
Solu-Medrol
Blood Withdrawn
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jul 23, 2025
ANZUPGO
NDA NDA219155
Sources
Details
Patent Cliff
Sep 19, 2031
Earliest patent expiration — generic entry possible after this date